In short
Gimeracil, a component of the drug combination S-1 (also known as Tegafur-Gimeracil-Oteracil), is being studied in various clinical trials for its potential in treating different types of cancer. These trials aim to evaluate the efficacy and safety of Gimeracil-containing treatments, either alone or in combination with other drugs, in patients with advanced or metastatic cancers such as colorectal, gastric, pancreatic, breast, and esophageal cancers.
At a glance
- Cancer Types Studied
- Colorectal, gastric, pancreatic, breast, esophageal, nasopharyngeal, cervical
- Common Drug Combinations
- S-1 (Tegafur-Gimeracil-Oteracil), often combined with other drugs like Bevacizumab, Fruquintinib, or immunotherapy agents
- Administration
- Typically oral, with dosages based on body surface area; common schedules include 2-4 weeks on, followed by a rest period
- Primary Outcomes Measured
- Progression-free survival, overall response rate, disease control rate, overall survival
- Potential Benefits
- Improved survival rates, tumor shrinkage, disease control in advanced cancers
- Common Side Effects
- Nausea, vomiting, diarrhea, fatigue, decreased blood cell counts
- Trial Phases
- Mostly Phase II, some Phase Ib/II combinations
What is GIMERACIL?
GIMERACIL is a component of a combination drug therapy known as S-1 or TS-1. This medication is typically combined with two other drugs: Tegafur and Oteracil Potassium. Together, these three components form a novel oral anticancer treatment.
S-1 (also known as Tegafur-Gimeracil-Oteracil) is a type of chemotherapy drug that belongs to the class of medications called antimetabolites. It works by interfering with the growth of cancer cells, ultimately leading to their destruction.
Conditions Treated with GIMERACIL
GIMERACIL, as part of the S-1 combination, is used to treat various types of cancer, including:
- Colorectal Cancer: S-1 is used in the treatment of advanced or metastatic colorectal cancer, especially when other treatments have failed.
- Gastric Cancer: It's approved for the treatment of advanced gastric (stomach) cancer in some countries.
- Pancreatic Cancer: S-1 is being studied for use in metastatic pancreatic cancer.
- Breast Cancer: Clinical trials have explored its use in advanced metastatic breast cancer.
- Esophageal Cancer: It's being investigated for use in advanced or metastatic esophageal squamous cell carcinoma.
- Cervical Cancer: Studies are ongoing to evaluate its efficacy in locally advanced cervical cancer.
Combination Therapies
GIMERACIL, as part of S-1, is often used in combination with other cancer treatments to enhance its effectiveness. Some common combinations include:
- S-1 with Bevacizumab: This combination is being studied for colorectal cancer treatment.
- S-1 with Gemcitabine: Used in pancreatic cancer treatment.
- S-1 with Docetaxel: Being studied for gastric cancer treatment.
- S-1 with Fruquintinib and Cadonilimab: This triple combination is being investigated for esophageal cancer.
Dosage and Administration
The dosage of S-1 (which contains GIMERACIL) can vary depending on the specific condition being treated and the patient's body surface area (BSA). Here are some general guidelines:
- For patients with BSA less than 1.25 m², the typical dose is 40 mg twice daily.
- For patients with BSA between 1.25 m² and 1.5 m², the dose is usually 50 mg twice daily.
- For patients with BSA greater than 1.5 m², the dose may be 60 mg twice daily.
S-1 is typically taken orally, twice daily, for 14 days followed by a 7-day rest period. This 21-day cycle is then repeated. However, the exact schedule can vary depending on the treatment plan and combination with other drugs.
Current Clinical Trials
Several clinical trials are currently underway to further investigate the efficacy of GIMERACIL (as part of S-1) in various cancers:
- A study combining S-1 with Fruquintinib for metastatic colorectal cancer.
- An investigation of S-1 as consolidation therapy after chemoradiotherapy in cervical cancer.
- A trial exploring S-1 with Gemcitabine and Nivolumab in metastatic pancreatic cancer.
- A study of S-1 combined with Fruquintinib and Cadonilimab in esophageal cancer.
Potential Side Effects
Like all medications, S-1 (containing GIMERACIL) can cause side effects. Common side effects may include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Loss of appetite
- Lowered blood cell counts, which can increase the risk of infection or bleeding
It's important to note that not everyone experiences these side effects, and your healthcare provider will monitor you closely during treatment.